TLDR
- ALAB dropped 7.2% to $104.41 on March 30, hitting an intraday low of $102.20 on well below-average trading volume
- The stock is now 60% below its 52-week high of $262.90 and trading under both its 50-day ($138.30) and 200-day ($162.90) moving averages
- Q4 revenue was up 91.8% year-over-year and EPS beat estimates by $0.07, with Q1 2026 guidance set at $0.53–$0.54 EPS
- Analysts remain bullish with a consensus “Moderate Buy” and an average price target of $202.22 — nearly double the current price
- Insiders sold around 384,292 shares worth $48.7 million in the last three months, though they still own 12.5% of the company
Astera Labs (ALAB) slid 7.2% on March 30, closing at $104.41 after touching an intraday low of $102.20. The stock had closed at $112.47 the session prior.
Astera Labs, Inc. Common Stock, ALAB
Volume was notably thin. Around 566,620 to 1.7 million shares changed hands depending on the session snapshot — well below the daily average of roughly 5.1–5.2 million shares. Light volume on a down day can sometimes reflect a lack of conviction rather than a wave of selling pressure.
The drop pushes ALAB deeper into a painful stretch. The stock now sits 60% below its 52-week high of $262.90, though it remains more than 120% above its 52-week low of $47.13.
Both moving averages are pointing the wrong way. The 50-day sits at $138.30 and the 200-day at $162.90 — well above Monday’s close — confirming the stock has been in a downtrend for some time.
Strong Fundamentals, Weak Chart
The fundamentals tell a different story. In Q4, Astera Labs posted revenue of $270.58 million, up 91.8% year-over-year and ahead of the $249.46 million analyst consensus. EPS came in at $0.58, beating estimates of $0.51 by $0.07. Net margin stood at 25.70% and return on equity was 16.12%.
For Q1 2026, the company guided EPS of $0.53 to $0.54. On a full-year basis, analysts expect $0.34 EPS on average.
Wall Street hasn’t given up. Of 23 analysts covering the stock, 15 have a Buy rating, six a Hold, and just one a Sell. The consensus stands at “Moderate Buy” or “Outperform” depending on the data provider. Average price targets range from $202 to $204 — implying upside of roughly 95–97% from current levels. Individual targets go as high as $250–$275.
Insiders Have Been Selling
That optimism from analysts doesn’t extend to the executive suite, at least not recently. Over the past three months, insiders sold around 384,292 shares worth approximately $48.7 million.
General Counsel Philip Mazzara sold 10,000 shares on March 2 at $117.47, reducing his stake by 7.24%. COO Sanjay Gajendra sold 94,971 shares in February at an average of $123.81, trimming his position by 5.84%.
Despite those sales, insiders collectively still own 12.5% of the company. Institutional investors hold about 60.5% of the float, and several have been adding to positions recently. Royal Bank of Canada grew its stake by 167.3% in Q1. AQR Capital Management boosted its position by 213.4%. Empowered Funds increased its holdings by 917.3%.
At a market cap of $16.79 billion and a P/E ratio of 80.39, the stock carries a growth premium. The beta of 1.75 reflects its tendency to move sharply in both directions.
As of the March 30 close, ALAB was trading at $104.01–$104.41, roughly 60% below its all-time high and well under every major analyst price target.
Considering a new stock? You may want to see what’s on our watchlist first.
Our team at Knockout Stocks follows top-performing analysts and market-moving trends to spot potential winners early. We’ve identified five stocks gaining quiet attention that could be worth watching now. Create your free account to unlock the full report and get ongoing stock insights.Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
